Symposium organized by the ULB on Monday September 16th, 2024 on the subject “Antimycobacterial drug development”. Location: Salle Solvay,building NO, Campus Plaine, Boulevard du Triomphe, 1050 Brussels. Qualified researchers will present keynote lectures and Belgian PhD students or postdoc will be able to present short communications.
The inscription is free but mandatory through the following link (closed on September 16th, 2024):
https://docs.google.com/forms/d/e/1FAIpQLSdc8gh3jqmaF6DY5Tqqxi5QSLvZElXywyOfXUYGrI6-lSANSw/viewform?usp=sf_link
Program divided in 4 sessions:
• New antimycobacterial and antimicrobial compounds in view
• New mycobacterial targets in view
• New drug regimens in view
• New antimycobacterial drug assessments in view
Among the qualified managers making an oral presentation:
- Prof. Jayanta Haldar (JNCASR, Bangalore, India) on « Vancomycin analogues in the pipeline of antimicrobial drug development”
- Prof. Alain Baulard (Institut Pasteur de Lille, France) on « Rewiring M.tuberculosis to reverse antibiotic resistance: Alpibectir from bench to bedside”
- Prof. Leen Rigouts (Institute of Tropical Medicine, Antwerp, Belgium) on “Genetic variants across phylogenetic lineages of Mycobacterium tuberculosis complex may cause resistance in drug-naïve populations”.
- Prof. Gilles Berger (Université Libre de Bruxelles) on « Exploring transition metal complexes for human diseases »
- Prof. Véronique Fontaine (Université Libre de Bruxelles) on “Why to target GroEL1 and PDIM biosynthesis to fight M. tuberculosis ”